A cost-analysis model for anticoagulant treatment in the hospital setting

References

• Janssen Pharmaceuticals, Inc. Xarelto Prescribing Information [online]. 2012. Available at http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf. [Last accessed 13 March 2013]
   Google Scholar
• Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510
   PubMed Web of Science ®Google Scholar
• Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-9
   PubMed Web of Science ®Google Scholar
• Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med Sep 2011;365:883-91
   PubMed Web of Science ®Google Scholar
• Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. JMCP 2007;13:475-86
   PubMed Web of Science ®Google Scholar
• Kozma CM, Slaton T, Paris A, et al. Cost and utilization of healthcare services for hip and knee replacement. J Med Econ 2013;16:888-96
   PubMedGoogle Scholar
• Kim MH, Johnston SS, Chu BC, et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circulation. Cardiovasc Qual Outcome 2011;4:313-20
   PubMed Web of Science ®Google Scholar
• Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th edn: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e278S-325S
   PubMed Web of Science ®Google Scholar
• RedBook. Truven Health Analytics: Average Wholesale Price (AWP). [online]. Available at http://sites.truvenhealth.com/redbook/index.html. [Last accessed 18 October 2012]
   Google Scholar
• AnalySource. AnalySource online: the online resource for drug pricing and deal information. [online]. Available at http://www.analysource.com. [Last accessed 3 January 2013]
   Google Scholar
• Clinical Diagnostic Laboratory Fee Schedule. Baltimore, MD: Center for Medicare and Medicaid Services, 2012. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/clinlab.html. Accessed September 4, 2012
   Google Scholar
• Laliberte F, Pilon D, Raut MK, et al. Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation? Curr Med Res Opin 2014;30:645–53
   Google Scholar
• van Bellen B, Bamber L, Correa de Carvalho F, et al. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin 2014;30:829--37
   PubMed Web of Science ®Google Scholar
• Weitz JI, Gross PL. New oral anticoagulants: which one should my patient use? Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2012;2012:536-40
   Google Scholar
• Aujesky D, Roy PM, Verschuren F, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet 2011;378:41-8
   PubMed Web of Science ®Google Scholar
• Bullano MF, Willey V, Hauch O, et al. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm 2005;11:663-73
   PubMedGoogle Scholar
• Beyer-Westendorf J, Lutzner J, Donath L, et al. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry. Thromb Haemost 2013;109:154-63
   PubMed Web of Science ®Google Scholar
• National statistics - principal diagnosis only. Outcomes by ICD-9-CM diagnosis codes. Rockville, MD: Agency for Healthcare Research and Quality, 2012. http://hcupnet.ahrq.gov/HCUPnet.jsp. Accessed August 31, 2012
   Google Scholar